Amoxicillin 500mg+ Clavulanic Acid 125mg Drug

• Application: Finishes Products
• Usage Mode: For oral administration
• Suitable for: Elderly, Children, Adult
• State: Solid
• Shape: Tablet
• Type: Biological Products
• Model NO.: 500mg
• Pharmaceutical Technology: Chemical Synthesis
• Transport Package: CTN
• Specification: 200MG

Product Description

INDICATION:
Amoxicillin 500mg +Clavulanic Acid 125mg Tablet is used in the treatment of bacterial infection; urinary tract infection; sinusitis; bronchitis; skin or soft tissue infection (and more), and belongs to the drug class beta-lactamase inhibitors. There is no proven risk in humans during pregnancy.


 

500MG+125MG

7tab*2/box, 300boxes/carton

If you a
re a distributor, please inquire with us about product registration, importing and/or marketing our products in your country or region.
If you are a consumer, don't hesitate to contact us about more information for this product.



As the world's leading large-scale professional pharmaceutical products trade and exchange event, CPHI provides an excellent platform for companies to expand into global markets and learn about industry dynamics and development trends. 
NOUVASANT (Booth No.: E3A26) which is a comprehensive pharmaceutical company specialized in R&D, manufacture, and export of medicines for human use, has participated in CPHI China for several consecutive years, showing our high-quality products and corporate brand image, expanding the international markets, and deepening international cooperation with all the partners all over the world.
Since its establishment, NOUVASANT has been committed to providing safe and effective health products for overseas markets based on the actual needs of customers, It's products have been successfully registered and sold in a number of regulatory markets in the world, and established long-term good relations of cooperation with overseas customers.
With the recognition from the 3rd selection activity of Top 100 Pharmaceutical Internationalization Companies, NOUVASANT will continue to tap into growth points, deploy strategic plans, and promote more cooperation in the international pharmaceutical markets continually.